Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 16 de 16
Filtrer
1.
Eur J Public Health ; 34(2): 361-367, 2024 Apr 03.
Article de Anglais | MEDLINE | ID: mdl-38224266

RÉSUMÉ

BACKGROUND: A population-based cervical cancer screening programme is implemented in the Czech Republic. However, participation is insufficient among women over 50 years. This study aimed to estimate the potential improvement in participation through directly mailed HPV self-sampling kits (HPVssk) compared with standard invitation letters in women aged 50-65 non-participating in screening. METHODS: The study recruited 1564 eligible women (no cervical cancer screening in the last 3 years or more, no previous treatment associated with cervical lesions or cervical cancer). Eight hundred women were mailed with an HPVssk (HPVssk group), and 764 women were sent a standard invitation letter (control group) inviting them to a routine screening (Pap test). The primary outcome was a comparison of the overall participation rate between study groups using a binominal regression model. RESULTS: The participation rate in the HPVssk group was 13.4% [95% confidence interval (CI) 11.2-15.9%; 7.4% of women returned the HPVssk and 6.0% attended gynaecological examination] and 5.0% (95% CI 3.6-6.8%) in the control group. Using the binominal regression model, the difference between the groups was estimated as 7.6% (95% CI 5.0-10.2%; P < 0.001). In the HPVssk group, 22% of women who returned HPVssk had a positive result and 70% of them underwent a follow-up examination. CONCLUSIONS: Compared with traditional invitation letters, the direct mailing of the HPVssk achieved a significantly higher participation rate, along with a notable HPV positivity rate among HPVssk responders. This approach offers a potentially viable method for engaging women who have not yet attended a cervical screening programme.


Sujet(s)
Infections à papillomavirus , Tumeurs du col de l'utérus , Femelle , Humains , Tumeurs du col de l'utérus/diagnostic , Tumeurs du col de l'utérus/prévention et contrôle , Infections à papillomavirus/diagnostic , Dépistage précoce du cancer/méthodes , Frottis vaginaux , République tchèque/épidémiologie , Dépistage de masse/méthodes
2.
Eur J Cancer Prev ; 33(2): 168-176, 2024 Mar 01.
Article de Anglais | MEDLINE | ID: mdl-37751376

RÉSUMÉ

OBJECTIVE: The substantial material and legislative investments in establishing and maintaining cytological screening in the Czech Republic represent barriers to a direct transition to primary HPV screening. Therefore, the LIBUSE project was implemented to test the efficacy of phasing in HPV DNA testing as a co-test to cytology in routine screening of women >30 years of age. METHODS: Women aged 30 to 60 years who underwent regular annual Pap smears were co-tested for HPV DNA with selective 16/18 genotyping at 3-year intervals. All HPV 16/18-positive cases and/or cases with a severe abnormality in cytology were sent for colposcopy; HPV non-16/18-positive cases and LSILs were graded using p16/Ki67 dual-stain cytology, and positive cases were sent for colposcopy. RESULTS: Overall, 2409 patients were included. After the first combined screening (year 'zero') visit, 7.4% of women were HPV-positive and 2.0% were HPV16/18-positive; only 8 women had severe Pap smear abnormalities. Triage by dual staining was positive in 21.9% of cases (28/128). Biopsy confirmed 34 high-grade precancer lesions. At the second combined visit (year 'three'), the frequency of HPV infection (5.3% vs. 7.4%) frequency of HPV16/18 (1.1% vs. 2.0%), referrals for colposcopy (35 vs. 83), and biopsy verified high-grade lesions (5 vs. 34) were significantly lower (all P  ≤ 0.001). CONCLUSION: The addition of HPV DNA testing with selective genotyping of HPV16/18 to existing cytology screening significantly increased the safety of the program. The gradual introduction of HPV testing was well received by healthcare professionals and patients, and can facilitate transformation of the cytology-based screening. ClinicalTrials.gov Identifier: NCT05578833.


Sujet(s)
Infections à papillomavirus , Dysplasie du col utérin , Tumeurs du col de l'utérus , Humains , Femelle , Adulte , Dysplasie du col utérin/diagnostic , Papillomavirus humain de type 16/génétique , Triage , Papillomavirus humain de type 18/génétique , Dépistage de masse , Test de Papanicolaou , ADN , Coloration et marquage , Dépistage précoce du cancer , Frottis vaginaux
3.
Mol Oncol ; 17(10): 2074-2089, 2023 10.
Article de Anglais | MEDLINE | ID: mdl-37491786

RÉSUMÉ

Oxysterols, oxidized derivatives of cholesterol, act in breast cancer (BC) as selective estrogen receptor modulators and affect cholesterol homeostasis, drug transport, nuclear and cell receptors, and other signaling proteins. Using data from three highly overlapping sets of patients (N = 162 in total) with early-stage estrogen-receptor-positive luminal BC-high-coverage targeted DNA sequencing (113 genes), mRNA sequencing, and full micro-RNA (miRNA) transcriptome microarrays-we describe complex oxysterol-related interaction (correlation) networks, with validation in public datasets (n = 538) and 11 databases. The ESR1-CH25H-INSIG1-ABCA9 axis was the most prominent, interconnected through miR-125b-5p, miR-99a-5p, miR-100-5p, miR-143-3p, miR-199b-5p, miR-376a-3p, and miR-376c-3p. Mutations in SC5D, CYP46A1, and its functionally linked gene set were associated with multiple differentially expressed oxysterol-related genes. STARD5 was upregulated in patients with positive lymph node status. High expression of hsa-miR-19b-3p was weakly associated with poor survival. This is the first study of oxysterol-related genes in BC that combines DNA, mRNA, and miRNA multiomics with detailed clinical data. Future studies should provide links between intratumoral oxysterol signaling depicted here, circulating oxysterol levels, and therapy outcomes, enabling eventual clinical exploitation of present findings.


Sujet(s)
Tumeurs du sein , microARN , Oxystérols , Humains , Femelle , Tumeurs du sein/anatomopathologie , ARN messager/génétique , microARN/génétique , microARN/métabolisme , Transcriptome/génétique
4.
Virchows Arch ; 482(2): 325-338, 2023 Feb.
Article de Anglais | MEDLINE | ID: mdl-36348031

RÉSUMÉ

Cauda equina neuroendocrine tumors (CENETs) are neoplasms of uncertain histogenesis with overlapping features between those of paragangliomas (PGs) and visceral neuroendocrine tumors (NETs). We have explored their biological relationship to both subsets of neuroendocrine neoplasms. The clinical and radiological features of a cohort of 23 CENETs were analyzed. A total of 21 cases were included in tissue microarrays, along with a control group of 38 PGs and 83 NETs. An extensive panel of antibodies was used to assess epithelial phenotype (cytokeratins, E-cadherin, EpCAM, Claudin-4, EMA, CD138), neuronal and neuroendocrine features (synaptophysin, chromogranin A, INSM1, neurofilaments, NeuN, internexin-α, calretinin), chromaffin differentiation (GATA3, Phox2b, tyrosine hydroxylase), and possible histogenesis (Sox2, T-brachyury, Oct3/4, Sox10). The cohort included 5 women (22%) and 18 men (78%). The average age at the time of surgery was 48.3 years (range from 21 to 80 years). The average diameter of the tumors was 39.27 mm, and invasion of surrounding structures was observed in 6/21 (29%) tumors. Follow-up was available in 16 patients (median 46.5 months). One tumor recurred after 19 months. No metastatic behavior and no endocrine activity were observed. Compared to control groups, CENETs lacked expression of epithelial adhesion molecules (EpCAM, CD138, E-cadherin, Claudin-4), and at the same time, they lacked features of chromaffin differentiation (GATA3, Phox2b, tyrosine hydroxylase). We observed no loss of SDHB. Cytokeratin expression was present in all CENETs. All the CENETs showed variable cytoplasmic expression of T-brachyury and limited nuclear expression of Sox2. These findings support the unique nature of the neoplasm with respect to NETs and PGs.


Sujet(s)
Queue de cheval , Tumeurs du système nerveux central , Tumeurs neuroendocrines , Paragangliome , Humains , Femelle , Tumeurs neuroendocrines/anatomopathologie , Molécule d'adhérence des cellules épithéliales , Queue de cheval/métabolisme , Queue de cheval/anatomopathologie , Queue de cheval/chirurgie , Claudine-4 , Tyrosine 3-monooxygenase , Récidive tumorale locale/anatomopathologie , Facteurs de transcription , Tumeurs du système nerveux central/anatomopathologie , Protéines de répression
5.
Biochimie ; 199: 158-169, 2022 Aug.
Article de Anglais | MEDLINE | ID: mdl-35525372

RÉSUMÉ

Oxysterols, oxidized derivatives of cholesterol, have been implicated in multiple pathologies, including cancer. In breast cancer, the link is especially strong due to interactions between oxysterols and estrogen receptor activity. Here, we provide the first dedicated study of 113 oxysterol-related genes in breast cancer patients of the luminal subtype, in terms of both their somatic and germline variability, using targeted high-throughput DNA sequencing of 100 normal-tumor pairs with very high coverage. In the full cohort, or subsets of patients stratified by therapy, we found 12 germline variants in ABCA1, ABCA8, ABCC1, GPR183, LDLR, MBTPS1, NR1I2, OSBPL2, OSBPL3, and OSBPL5 to associate with poor survival of patients and variants in ABCA8, ABCG2, and HSD3B7 (three in total) associated with better survival. However, no associations remained significant after correction for multiple tests. Analysis of somatic variants revealed significantly (after FDR correction) poorer survival in patients mutated in CYP46A1 and 9 interacting (according to STRING analysis) genes, as well as in OSBPL3 and a set of 20 genes that collectively associated with the progesterone receptor status of patients. We propose further exploration of these genes in an integrative manner together with gene expression and epigenomic data.


Sujet(s)
Tumeurs du sein , Oxystérols , Récepteurs aux stéroïdes , Tumeurs du sein/génétique , Tumeurs du sein/anatomopathologie , Études de cohortes , Femelle , Cellules germinales/métabolisme , Séquençage nucléotidique à haut débit , Humains , Oxystérols/métabolisme , Récepteurs aux stéroïdes/génétique
6.
Clin Chem Lab Med ; 55(1): 111-122, 2017 Jan 01.
Article de Anglais | MEDLINE | ID: mdl-27327132

RÉSUMÉ

BACKGROUND: Apoptosis plays a critical role in cancer cell survival and tumor development. We provide a hypothesis-generating screen for further research by exploring the expression profile and genetic variability of caspases (2, 3, 7, 8, 9, and 10) in breast carcinoma patients. This study addressed isoform-specific caspase transcript expression and genetic variability in regulatory sequences of caspases 2 and 9. METHODS: Gene expression profiling was performed by quantitative real-time PCR in tumor and paired non-malignant tissues of two independent groups of patients. Genetic variability was determined by high resolution melting, allelic discrimination, and sequencing analysis in tumor and peripheral blood lymphocyte DNA of the patients. RESULTS: CASP3 A+B and S isoforms were over-expressed in tumors of both patient groups. The CASP9 transcript was down-regulated in tumors of both groups of patients and significantly associated with expression of hormonal receptors and with the presence of rs4645978-rs2020903-rs4646034 haplotype in the CASP9 gene. Patients with a low intratumoral CASP9A/B isoform expression ratio (predicted to shift equilibrium towards anti-apoptotic isoform) subsequently treated with adjuvant chemotherapy had a significantly shorter disease-free survival than those with the high ratio (p=0.04). Inheritance of CC genotype of rs2020903 in CASP9 was associated with progesterone receptor expression in tumors (p=0.003). CONCLUSIONS: Genetic variability in CASP9 and expression of its splicing variants present targets for further study.


Sujet(s)
Tumeurs du sein/enzymologie , Tumeurs du sein/génétique , Caspases/génétique , Régulation de l'expression des gènes tumoraux , Variation génétique/génétique , Thérapie moléculaire ciblée , Transcription génétique , Caspase-9/génétique , Caspase-9/métabolisme , Caspases/métabolisme , Femelle , Analyse de profil d'expression de gènes , Humains , Adulte d'âge moyen
7.
Biomed Pharmacother ; 83: 857-864, 2016 Oct.
Article de Anglais | MEDLINE | ID: mdl-27505863

RÉSUMÉ

Microtubules are vitally important for eukaryotic cell division. Therefore, we evaluated the relevance of mitotic kinesin KIF14, protein-regulating cytokinesis 1 (PRC1), and citron kinase (CIT) for the prognosis of breast carcinoma patients. Transcript levels were assessed by quantitative real-time PCR in tissues from two independent groups of breast carcinoma patients and compared with clinical data. Tissue PRC1 protein levels were estimated using immunoblotting, and the PRC1 tagged haplotype was analyzed in genomic DNA. A functional study was performed in MDA-MB-231 cells in vitro. KIF14, PRC1, and CIT transcripts were overexpressed in tumors compared with control tissues. Tumors without expression of hormonal receptors or high-grade tumors expressed significantly higher KIF14 and PRC1 levels than hormonally-positive or low-grade tumors. Patients with high intra-tumoral PRC1 levels had significantly worse disease-free survival than patients with low levels. PRC1 rs10520699 and rs11852999 polymorphisms were associated with PRC1 transcript levels, but not with patients survival. Paclitaxel-induced PRC1 expression, but PRC1 knockdown did not modify the paclitaxel cytotoxicity in vitro. PRC1 overexpression predicts poor disease-free survival of patients with breast carcinomas. Genetic variability of PRC1 and the protein interaction with paclitaxel cytotoxicity do not explain this association.


Sujet(s)
Tumeurs du sein/génétique , Protéines du cycle cellulaire/génétique , Protéines du cycle cellulaire/métabolisme , Survie sans rechute , Régulation de l'expression des gènes tumoraux , Tumeurs du sein/anatomopathologie , Études cas-témoins , Mort cellulaire/effets des médicaments et des substances chimiques , Lignée cellulaire tumorale , Femelle , Régulation de l'expression des gènes tumoraux/effets des médicaments et des substances chimiques , Techniques de knock-down de gènes , Humains , Estimation de Kaplan-Meier , Paclitaxel/pharmacologie , Polymorphisme génétique , ARN messager/génétique , ARN messager/métabolisme
8.
Medicine (Baltimore) ; 93(28): e255, 2014 Dec.
Article de Anglais | MEDLINE | ID: mdl-25526449

RÉSUMÉ

Metabolism of anticancer drugs affects their antitumor effects. This study has investigated the associations of gene expression of enzymes metabolizing anticancer drugs with therapy response and survival of breast carcinoma patients. Gene expression of 13 aldo-keto reductases (AKRs), carbonyl reductase 1, and 10 cytochromes P450 (CYPs) was assessed using quantitative real-time polymerase chain reaction in tumors and paired adjacent nonneoplastic tissues from 68 posttreatment breast carcinoma patients. Eleven candidate genes were then evaluated in an independent series of 50 pretreatment patients. Protein expression of the most significant genes was confirmed by immunoblotting. AKR1A1 was significantly overexpressed and AKR1C1-4, KCNAB1, CYP2C19, CYP3A4, and CYP3A5 downregulated in tumors compared with control nonneoplastic tissues after correction for multiple testing. Significant association of CYP2B6 transcript levels in tumors with expression of hormonal receptors was found in the posttreatment set and replicated in the pretreatment set of patients. Significantly higher intratumoral levels of AKR1C1, AKR1C2, or CYP2W1 were found in responders to neoadjuvant chemotherapy compared with nonresponders. Patients with high AKR7A3 or CYP2B6 levels in the pretreatment set had significantly longer disease-free survival than patients with low levels. Protein products of AKR1C1, AKR1C2, AKR7A3, CYP3A4, and carbonyl reductase (CBR1) were found in tumors and those of AKR1C1, AKR7A3, and CBR1 correlated with their transcript levels. Small interfering RNA-directed knockdown of AKR1C2 or vector-mediated upregulation of CYP3A4 in MDA-MB-231 model cell line had no effect on cell proliferation after paclitaxel treatment in vitro. Prognostic and predictive roles of drug-metabolizing enzymes strikingly differ between posttreatment and pretreatment breast carcinoma patients. Mechanisms of action of AKR1C2, AKR7A3, CYP2B6, CYP3A4, and CBR1 should continue to be further followed in breast carcinoma patients and models.


Sujet(s)
Aldose reductase/génétique , Tumeurs du sein/génétique , Cytochrome P-450 enzyme system/génétique , Régulation de l'expression des gènes tumoraux , ARN tumoral/génétique , Aldose reductase/biosynthèse , Aldo-keto reductases , Tumeurs du sein/métabolisme , Tumeurs du sein/anatomopathologie , Prolifération cellulaire , Cytochrome P-450 enzyme system/biosynthèse , Femelle , Cytométrie en flux , Humains , Immunotransfert , Pronostic , Études prospectives , Réaction de polymérisation en chaine en temps réel , Cellules cancéreuses en culture
9.
PLoS One ; 9(7): e101740, 2014.
Article de Anglais | MEDLINE | ID: mdl-25078270

RÉSUMÉ

OBJECTIVES: ATP-Binding Cassette (ABC) transporters may cause treatment failure by transporting of anticancer drugs outside of the tumor cells. Multidrug resistance-associated protein 1 coded by the ABCC1 gene has recently been suggested as a potential prognostic marker in breast cancer patients. This study aimed to explore tagged haplotype covering nucleotide binding domain 1 of ABCC1 in relation with corresponding transcript levels in tissues and clinical phenotype of breast cancer patients. METHODS: The distribution of twelve ABCC1 polymorphisms was assessed by direct sequencing in peripheral blood DNA (n = 540). RESULTS: Tumors from carriers of the wild type genotype in rs35623 or rs35628 exhibited significantly lower levels of ABCC1 transcript than those from carriers of the minor allele (p = 0.003 and p = 0.004, respectively). The ABCC1 transcript levels significantly increased in the order CT-GT>CC-GT>CC-GG for the predicted rs35626-rs4148351 diplotype. Chemotherapy-treated patients carrying the T allele in rs4148353 had longer disease-free survival than those with the GG genotype (p = 0.043). On the other hand, hormonal therapy-treated patients with the AA genotype in rs35628 had significantly longer disease-free survival than carriers of the G allele (p = 0.012). CONCLUSIONS: Taken together, our study shows that genetic variability in the nucleotide binding domain 1 has a significant impact on the ABCC1 transcript level in the target tissue and may modify survival of breast cancer patients.


Sujet(s)
Tumeurs du sein/génétique , Protéines associées à la multirésistance aux médicaments/génétique , Polymorphisme de nucléotide simple , ARN messager/génétique , Analyse de survie , Sujet âgé , Tumeurs du sein/physiopathologie , Femelle , Humains , Adulte d'âge moyen , Protéines associées à la multirésistance aux médicaments/métabolisme
10.
Eur J Pediatr ; 2013 Nov 15.
Article de Anglais | MEDLINE | ID: mdl-24233405

RÉSUMÉ

The aim of this study was to assess the accuracy of serological tests in combination with clinical symptoms for diagnosing celiac disease (CD) according to the new proposed European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) criteria. We retrospectively assessed children and adolescents aged 16 months -19 years who were examined for suspicion of CD (n = 345). Evaluation of clinical symptoms and the presence of tissue transglutaminase (anti-TG-IgA) and endomysial antibodies (EMA-IgA) as well as intestinal biopsies was performed in all patients. Human leukocyte antigens (HLAs) were not included. Among 345 biopsied children, 213 (62 %) children had anti-TG titers >10 times the upper limit of normal (ULN) and positive EMA antibodies. Ninety-nine (29 %) children also had symptoms suggestive of CD in addition to EMA positivity and elevated titers of anti-TG >10 times the ULN. In patients who were asymptomatic, but positive for EMA, and had anti-TG antibodies >10 times the ULN, the specificity of tests for Marsh 2-3 was only 85 %, while in symptomatic patients with the same antibodies levels, the specificity was 99 %. Conclusion: Our results reveal that intestinal biopsies could be omitted in 28 % of patients when the new ESPGHAN guidelines are applied. Due to high accuracy of serological tests in combination with clinical symptoms for diagnosis of CD, the new guideline seems to be applicable even without the use of HLA testing.

11.
Pathol Res Pract ; 209(7): 433-40, 2013 Jul.
Article de Anglais | MEDLINE | ID: mdl-23726929

RÉSUMÉ

Breast cancer characteristics obtained at the time of diagnosis are important for setting the basic strategy of the treatment. Reliability of preoperative investigation differs for various features of the disease. The aim of this study was to ascertain the agreements and differences between preoperative and postoperative values. This retrospective study analyzed the results of 617 women with primary surgery of the breast and axilla. Cohen's kappa coefficient has been employed to measure the degree of agreement between preoperative and postoperative values. Substantial or "almost perfect" agreement has been documented for the histological type of the tumors, their histopathological grade, proliferation index Ki67, as well as for estrogen, progesterone, and HER-2/neu receptors. Substantial differences exist between preoperative and postoperative diagnoses of invasiveness of the tumor, determination of the size of the tumors, and the number of tumor foci. Preoperative imaging and clinical examination of lymph nodes exhibited unacceptably high false negative rates. Heterogeneity of breast cancer cell population, methodology of histology examinations, and insufficient imaging of lymph nodes are the major limitations precluding satisfactory accuracy of preoperative diagnosis. Preoperatively diagnosed in situ carcinomas, as well as multifocal lesions, were the most often sources of diagnostic failures.


Sujet(s)
Tumeurs du sein/chirurgie , Carcinomes/chirurgie , Mastectomie , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Marqueurs biologiques tumoraux/métabolisme , Tumeurs du sein/métabolisme , Tumeurs du sein/anatomopathologie , Carcinomes/métabolisme , Carcinomes/secondaire , Épithélioma in situ/métabolisme , Épithélioma in situ/anatomopathologie , Épithélioma in situ/chirurgie , Prolifération cellulaire , République tchèque , Faux négatifs , Femelle , Humains , Métastase lymphatique , Adulte d'âge moyen , Grading des tumeurs , Invasion tumorale , Valeur prédictive des tests , Reproductibilité des résultats , Études rétrospectives , Résultat thérapeutique , Charge tumorale , Jeune adulte
12.
Pharmacogenomics ; 14(5): 515-29, 2013 Apr.
Article de Anglais | MEDLINE | ID: mdl-23556449

RÉSUMÉ

AIM: ATP-binding cassette (ABC) transporters contribute to development of resistance to anticancer drugs via ATP-dependent drug efflux. A major goal of our study was to investigate associations between the expression of ABC transporters and outcome of breast carcinoma patients. PATIENTS & METHODS: Transcript levels of all 49 human ABC transporters were determined in post-treatment tumor and non-neoplastic tissue samples from 68 breast carcinoma patients treated by neoadjuvant chemotherapy. Six ABC transporters were then evaluated in independent series of 100 pretreatment patients. RESULTS: ABCA5/6/8/9/10, ABCB1/5/11, ABCC6/9, ABCD2/4, ABCG5 and ABCG8 were significantly downregulated and ABCA2/3/7/12, ABCB2/3/8/9/10, ABCC1/4/5/10/11/12, ABCD1/3, ABCE1, ABCF1/2/3 and ABCG1 were upregulated in post-treatment tumors compared with non-neoplastic tissues. Significant associations of intratumoral levels of ABCC1 and ABCC8 with grade and expression of hormonal receptors were found in both sets of patients. ABCA12, ABCA13 and ABCD2 levels were significantly associated with the response to neoadjuvant chemotherapy in post-treatment patients. Protein expression of ABCA12, ABCC8 and ABCD2 in tumor tissues of patients with breast carcinoma was observed by immunoblotting for the first time. CONCLUSION: ABCA12, ABCA13, ABCC1, ABCC8 and ABCD2 present potential modifiers of progression and response to the chemotherapy of breast carcinoma.


Sujet(s)
Transporteurs ABC/génétique , Tumeurs du sein/traitement médicamenteux , Tumeurs du sein/génétique , Carcinomes/traitement médicamenteux , Carcinomes/génétique , Transporteurs ABC/métabolisme , Antinéoplasiques/administration et posologie , Tumeurs du sein/anatomopathologie , Carcinomes/anatomopathologie , Femelle , Analyse de profil d'expression de gènes , Régulation de l'expression des gènes tumoraux , Études d'associations génétiques , Humains , Adulte d'âge moyen , Traitement néoadjuvant
13.
Future Oncol ; 9(3): 427-38, 2013 Mar.
Article de Anglais | MEDLINE | ID: mdl-23469978

RÉSUMÉ

AIM: A role of caspase-2 in chemotherapy-induced apoptosis has been suggested. Our study aimed to evaluate the prognostic and predictive importance of caspase-2 isoforms in breast cancer patients. MATERIALS & METHODS: Caspase-2L and -2S transcript levels were determined in paired tumor and non-malignant control tissues from 64 patients after neoadjuvant chemotherapy and 100 pretreatment patients (general set) by real-time PCR with absolute quantification. RESULTS: Low but statistically significant upregulation of caspase-2L in tumor versus control tissues was observed in both sets. Significant associations of the levels of caspase-2L, -2S or S/L ratio with clinical prognostic factors were observed. However, none of these associations were confirmed in both sets. Levels of caspase-2 isoforms or the S/L ratio did not significantly associate with progression-free survival in the general set or with chemotherapy response in the neoadjuvant set. CONCLUSION: Our results suggest that the role of caspase-2 isoforms in the progression of breast cancer may considerably differ between pre- and post-chemotherapy patients.


Sujet(s)
Tumeurs du sein/enzymologie , Carcinome canalaire du sein/enzymologie , Caspase-2/métabolisme , Cysteine endopeptidases/métabolisme , ARN messager/métabolisme , Adulte , Sujet âgé , Tumeurs du sein/mortalité , Carcinome canalaire du sein/mortalité , Caspase-2/génétique , Traitement médicamenteux adjuvant , Cysteine endopeptidases/génétique , Femelle , Fréquence d'allèle , Humains , Isoenzymes/génétique , Isoenzymes/métabolisme , Estimation de Kaplan-Meier , Adulte d'âge moyen , Traitement néoadjuvant , ARN messager/génétique , Analyse de séquence d'ADN , Régulation positive
14.
Clin Chem Lab Med ; 50(11): 1999-2007, 2012 Nov.
Article de Anglais | MEDLINE | ID: mdl-23093106

RÉSUMÉ

BACKGROUND: The ABCB1 gene encodes P-glycoprotein implicated in the development of cellular drug resistance. The aim of this study was to develop high-resolution melting (HRM) analysis for determination of ABCB1 polymorphisms and evaluate their associations with clinical data of breast carcinoma patients. METHODS: HRM analysis was designed to assess five single nucleotide polymorphisms (SNPs) in ABCB1 (rs2214102, rs1128503, rs2032582, rs2032583 and rs1045642) in genomic DNA from 103 breast carcinoma patients. Results were confirmed by direct DNA sequencing. RESULTS: HRM analysis revealed distinct patterns of melting curves for the respective genotypes of all followed SNPs. Sensitivity of HRM analysis compared with direct DNA sequencing was superior (97.1% vs. 93.9%). The overall accuracy of HRM was 97.6%. The coefficients of variation in replicate experiments encompassed the range 0.002%-0.038%. On the basis of the examined SNPs, one strong haplotype block containing rs2032582 and rs1128503 SNPs was identified. Significant associations of rs2032582 SNP with tumor size, negative HER-2/neu status, and family history of breast carcinoma were found. Patients carrying the ancestral homozygous genotype (GG) in rs2214102 had significantly worse progression-free survival in comparison with carriers of the non-ancestral allele (A) in the adjuvant set (p=0.005). CONCLUSIONS: A rapid, accurate, low-cost and time-effective method for screening ABCB1 SNPs was developed. Significant associations of ABCB1 rs2032582 and rs2214102 SNPs with prognostic factors and survival of patients were found.


Sujet(s)
Glycoprotéine P/génétique , Tumeurs du sein/diagnostic , Tumeurs du sein/génétique , Polymorphisme de nucléotide simple , Analyse de séquence d'ADN/méthodes , Température de transition , Sous-famille B de transporteurs à cassette liant l'ATP , Tumeurs du sein/thérapie , Femelle , Humains , Adulte d'âge moyen , Dénaturation d'acide nucléique , Pronostic , Résultat thérapeutique
15.
Tex Heart Inst J ; 38(2): 191-3, 2011.
Article de Anglais | MEDLINE | ID: mdl-21494535

RÉSUMÉ

Infected cardiac myxoma is a rare cause of endocarditis. The finding of coexisting infected cardiac myxomas is highly unusual. Herein, we present the case of a 58-year-old woman with a low-grade fever. Laboratory findings strongly indicated inflammation, and blood cultures detected Staphylococcus species. Echocardiograms revealed mobile masses in the area of the mitral valve. Transesophageal echocardiograms showed 2 formations that arose from opposite sides of the mitral annulus and protruded into the left ventricle during systole. During emergency surgery, 2 abnormal growths with numerous vegetations were completely excised. The diagnosis of myxoma was confirmed upon histologic evaluation. Microbiological and polymerase chain reaction analysis of the myxomas detected the bacterial strain Enterococcus faecalis. Five months postoperatively, the patient showed no signs of recurrent infection and had a normal echocardiographic appearance.This report is the first of an infected cardiac myxoma in the Czech population and one of approximately 60 reports in the medical literature from 1956 to the present. In addition to the case of our patient, we discuss the discrepancy between the bacteriologic findings.


Sujet(s)
Endocardite bactérienne/microbiologie , Enterococcus faecalis/isolement et purification , Tumeurs du coeur/microbiologie , Myxome/microbiologie , Tumeurs primitives multiples , Staphylococcus/isolement et purification , Antibactériens/usage thérapeutique , Techniques bactériologiques , Procédures de chirurgie cardiaque , Échocardiographie transoesophagienne , Endocardite bactérienne/imagerie diagnostique , Endocardite bactérienne/thérapie , Enterococcus faecalis/génétique , Femelle , Tumeurs du coeur/complications , Tumeurs du coeur/imagerie diagnostique , Tumeurs du coeur/thérapie , Humains , Adulte d'âge moyen , Myxome/complications , Myxome/imagerie diagnostique , Myxome/thérapie , Réaction de polymérisation en chaîne , Résultat thérapeutique
16.
Cancer ; 117(20): 4606-16, 2011 Oct 15.
Article de Anglais | MEDLINE | ID: mdl-21437896

RÉSUMÉ

BACKGROUND: Sentinel lymph node biopsy (SLNB) is a widely used staging method for patients with early breast cancer. Neoadjuvant chemotherapy modifies the anatomical conditions in the breast and axilla, and thus SLNB remains controversial in patients treated preoperatively. The aim of this study was to demonstrate the reliability and accuracy of this procedure in this particular group of patients. METHODS: The retrospective study analyzed medical records of patients diagnosed with primary breast cancer between the years 2005 and 2009. Of the patients treated by neoadjuvant therapy, 343 underwent lymphatic mapping to identify sentinel lymph nodes, and these were included in the analysis. RESULTS: The overall detection rate of sentinel lymph nodes was 80.8%. It was strongly influenced by clinical lymph node status (significantly higher success rate in lymph node-negative patients); higher detection rates were also associated with age <50 years, estrogen receptor positivity, lower proliferation index, and absent lymphovascular space invasion. The false-negative rate was 19.5% and was only marginally significantly dependent on lymphovascular space invasion. The overall accuracy of the method was 91.5%. CONCLUSIONS: By using the present technique, sentinel lymph node biopsy cannot be recommended as a reliable predictor of axillary lymph node status when performed at the authors' institution after neoadjuvant chemotherapy. Infrequent use of blue dye for lymphatic mapping, low number of resected sentinel lymph nodes, and absence of any selection among patients included in the study could be the main factors responsible for the low detection rate and high false-negative rate.


Sujet(s)
Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Tumeurs du sein/traitement médicamenteux , Tumeurs du sein/anatomopathologie , Noeuds lymphatiques/anatomopathologie , Traitement néoadjuvant/méthodes , Biopsie de noeud lymphatique sentinelle , Adulte , Sujet âgé , Aisselle , Marqueurs biologiques tumoraux/analyse , Tumeurs du sein/composition chimique , Tumeurs du sein/chirurgie , Traitement médicamenteux adjuvant , Faux négatifs , Femelle , Humains , Noeuds lymphatiques/chirurgie , Métastase lymphatique , Adulte d'âge moyen , Valeur prédictive des tests , Reproductibilité des résultats , Études rétrospectives , Sensibilité et spécificité
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...